Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6620562rdf:typepubmed:Citationlld:pubmed
pubmed-article:6620562lifeskim:mentionsumls-concept:C1274104lld:lifeskim
pubmed-article:6620562lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:6620562lifeskim:mentionsumls-concept:C0055000lld:lifeskim
pubmed-article:6620562lifeskim:mentionsumls-concept:C0144299lld:lifeskim
pubmed-article:6620562pubmed:issue5lld:pubmed
pubmed-article:6620562pubmed:dateCreated1983-11-23lld:pubmed
pubmed-article:6620562pubmed:abstractTextFollowing results were obtained from intravenous administration of T-1982 (cefbuperazone) 1 g by measuring its concentrations in uterine arterial serum, cubital venous serum, oviduct, ovary and several sites in uterine tissue. Endometrium showed the highest concentration among various uterine tissues by any administration (bolus injection, dripping infusion for 1 or 2 hours). Transfer concentrations about 1 hour after the end of 1 hour drip infusion proved to be almost the same as 2 hours drip infusion. In the field of obstetrics and gynecology, it was considered that T-1982 has good efficacy in infections especially caused by E. coli, Klebsiella and Proteus.lld:pubmed
pubmed-article:6620562pubmed:languagejpnlld:pubmed
pubmed-article:6620562pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6620562pubmed:citationSubsetIMlld:pubmed
pubmed-article:6620562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6620562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6620562pubmed:statusMEDLINElld:pubmed
pubmed-article:6620562pubmed:monthMaylld:pubmed
pubmed-article:6620562pubmed:issn0368-2781lld:pubmed
pubmed-article:6620562pubmed:authorpubmed-author:GotoKKlld:pubmed
pubmed-article:6620562pubmed:authorpubmed-author:TaguchiKKlld:pubmed
pubmed-article:6620562pubmed:authorpubmed-author:NaritaJJlld:pubmed
pubmed-article:6620562pubmed:authorpubmed-author:ShitaraYYlld:pubmed
pubmed-article:6620562pubmed:issnTypePrintlld:pubmed
pubmed-article:6620562pubmed:volume36lld:pubmed
pubmed-article:6620562pubmed:ownerNLMlld:pubmed
pubmed-article:6620562pubmed:authorsCompleteYlld:pubmed
pubmed-article:6620562pubmed:pagination919-24lld:pubmed
pubmed-article:6620562pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:6620562pubmed:meshHeadingpubmed-meshheading:6620562-...lld:pubmed
pubmed-article:6620562pubmed:meshHeadingpubmed-meshheading:6620562-...lld:pubmed
pubmed-article:6620562pubmed:meshHeadingpubmed-meshheading:6620562-...lld:pubmed
pubmed-article:6620562pubmed:meshHeadingpubmed-meshheading:6620562-...lld:pubmed
pubmed-article:6620562pubmed:meshHeadingpubmed-meshheading:6620562-...lld:pubmed
pubmed-article:6620562pubmed:meshHeadingpubmed-meshheading:6620562-...lld:pubmed
pubmed-article:6620562pubmed:meshHeadingpubmed-meshheading:6620562-...lld:pubmed
pubmed-article:6620562pubmed:meshHeadingpubmed-meshheading:6620562-...lld:pubmed
pubmed-article:6620562pubmed:meshHeadingpubmed-meshheading:6620562-...lld:pubmed
pubmed-article:6620562pubmed:meshHeadingpubmed-meshheading:6620562-...lld:pubmed
pubmed-article:6620562pubmed:year1983lld:pubmed
pubmed-article:6620562pubmed:articleTitle[Fundamental study on T-1982 (cefbuperazone) in obstetrics and gynecology].lld:pubmed
pubmed-article:6620562pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6620562pubmed:publicationTypeEnglish Abstractlld:pubmed